Health: Cancer Drugs Fund

Baroness Morgan of Drefelin Excerpts
Monday 14th November 2011

(13 years, 1 month ago)

Lords Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Asked By
Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin
- Hansard - -



To ask Her Majesty’s Government what assessment they have made of the effectiveness of the cancer drug fund.

Earl Howe Portrait The Parliamentary Under-Secretary of State, Department of Health (Earl Howe)
- Hansard - - - Excerpts

My Lords, since October 2010, more than 7,500 patients in England have benefited from the additional funding we have provided for cancer drugs. The £600 million we have committed over three years will improve the lives of many thousands more cancer sufferers, giving them precious extra time with their loved ones.

Baroness Morgan of Drefelin Portrait Baroness Morgan of Drefelin
- Hansard - -

My Lords, I remind the House of my interest as chief executive of a cancer research charity. Can the Minister share with the House thoughts on plans for the fund, following the abolition of strategic health authorities which are currently responsible for administering the fund? Will he share with us any thoughts the department has about emerging patterns of variation in access to the fund? I appreciate that it is a new fund and that patterns are difficult to see in a field where there are small numbers. I would, however, be interested to know what steps the department is taking to issue further advice on that question.

Earl Howe Portrait Earl Howe
- Hansard - - - Excerpts

My Lords, I pay tribute to the noble Baroness for her work in this area. She asked what would happen when strategic health authorities are abolished. Arrangements from 1 April 2013, which is the planned abolition date, and beyond will be the subject of discussions between my department and the NHS Commissioning Board Authority. So I cannot give her definite news yet on that front.

I know that the regional clinical panels are using their own judgment to come to decisions, and it is entirely right that they should. At the same time, they are alive to apparent variations in the drugs that are being made available through the fund in different regions, and I understand that the SHA clinical panels are working collectively now to better understand the reasons for those differences.